NEW YORK (GenomeWeb) – Agilent Technologies today announced the extension of a co-marketing agreement with MRM Proteomics.
The extension expands a deal between the companies reached in September 2012, and will allow the partners to improve their combined proteomics solutions comprising reagents kits, hardware, and software, Agilent said.
Based in Vancouver, British Columbia, MRM Proteomics offers protein quantitation, biomarker, and proteomics services to drug manufacturers, biotech, and diagnostics customers. It recently named Gary Krupp as its CEO as it continues its efforts to bring MALDI-TOF-based protein assays to the clinic.